rosiglitazone has been researched along with Dyslipidemia in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (60.53) | 29.6817 |
| 2010's | 15 (39.47) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Broderick, CL; Canada, E; Etgen, GJ; Gonzalez, I; Lamar, J; Mantlo, N; Montrose-Rafizadeh, C; Oldham, BA; Osborne, JJ; Shi, Q; Winneroski, LL; Xie, C; Xu, Y; York, J; Yumibe, N; Zink, R | 1 |
| Cap, M; Chang, C; Cheng, PT; Chu, C; Devasthale, P; Doweyko, AM; Farrelly, D; Gu, L; Hariharan, N; Harrity, T; Hosagrahara, V; Kadiyala, P; Kunselman, L; Lippy, J; Locke, K; Morgan, N; Muckelbauer, J; O'Malley, K; Ponticiello, R; Ryono, D; Wang, W; Zahler, R; Zebo, R; Zhang, L | 1 |
| Bénardeau, A; Benz, J; Binggeli, A; Blum, D; Boehringer, M; Grether, U; Hilpert, H; Kuhn, B; Märki, HP; Meyer, M; Mohr, P; Püntener, K; Raab, S; Ruf, A; Schlatter, D | 1 |
| Akiyama, TE; Berger, JP; Chang, CH; Doebber, TW; Einstein, M; Liu, K; Liu, W; McCann, ME; Meinke, PT; Wood, HB | 1 |
| Bhatia, G; Kumar, A; Maurya, RA; Sharma, S; Srivastava, AK; Srivastava, SP; Tamrakar, AK; Tripathi, VD | 1 |
| Haq, W; Katti, SB; Raza, S; Srivastava, AK; Srivastava, DS; Srivastava, SP | 1 |
| Agejas Francisco, J; Bocchinfuso, WP; Bueno, AB; Cannady, EA; Cox, A; Genin, MJ; Jones, TM; Manninen, PR; Michael, LF; Michael, MD; Montrose-Rafizadeh, C; Raddad, E; Reidy, C; Stille, JR | 1 |
| Lin, CH; Shih, CC; Shlau, MT; Wu, JB | 1 |
| Gao, R; Guo, T; Hu, X; Li, J; Liu, Z; Mei, H; Ming, Y; Song, Y; Wang, B; Wu, C; Xiao, L; Xiao, X; Zhang, Y | 1 |
| Bouillet, B; Brindisi, MC; Duvillard, L; Monier, S; Perségol, L; Petit, JM; Vergès, B | 1 |
| Sun, B; Yan, WJ; Zhang, WL; Zou, ZP | 1 |
| Barakat, W; El-Maraghy, N; Reda, E; Saleh, S | 1 |
| Han, JS; Park, MH | 1 |
| Abbasi, F; Chen, YD; Farin, HM; Lamendola, C; Reaven, GM | 1 |
| Derosa, G; Salvadeo, SA | 1 |
| Berneis, K; Christ, ER; Rini, GB; Rizzo, M; Spinas, GA | 1 |
| Baran, RW; Minshall, ME; Pandya, BJ; St Charles, M; Tunis, SL | 1 |
| Chalasani, N; Vuppalanchi, R | 1 |
| Bowsman, M; Chen, M; Cordover, D; Fordstrom, P; Hale, C; Helmering, J; Kaufman, SA; Lloyd, DJ; Véniant, MM; Wang, M; Zhou, M | 1 |
| Ahn, CW; Cha, BS; Kang, ES; Kim, DH; Kim, SK; Lee, HC; Lee, JH; Park, SE | 1 |
| Chang, YH; Hong, SI; Hong, YJ; Im, M; Kim, M; Lee, DY; Lee, JK; Lee, YY | 1 |
| Magkos, F; Mantzoros, CS | 1 |
| Falk, E; Glien, M; Glombik, H; Herling, AW; Korn, M; Linz, W; Rütten, H; Schäfer, HL; Wendler, W | 1 |
| Wilding, JP | 1 |
| Choi, MS; Do, GM; Jeon, SM; Jung, UJ; Kwon, EY; McGregor, RA; Park, HJ | 1 |
| Cha, BS; Kang, ES; Kim, HJ; Kim, HM; Lee, BW; Lee, HC; Moon, JH; Yang, AH | 1 |
| Fiévet, C; Fruchart, JC; Hennuyer, N; Mezdour, H; Staels, B; Tailleux, A; Torpier, G | 1 |
| Altuntas, Y; Basat, O; Seber, S; Ucak, S | 1 |
| Bell, DS | 1 |
| Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ | 1 |
| Berhanu, P; Demissie, S; Fleck, PR; Khan, MA; Kipnes, MS; Kupfer, SF; Perez, AT; Spanheimer, RC | 1 |
| Chen, JW; Jen, HL; Lin, SJ; Yin, WH; Young, MS | 1 |
| Arnerup, G; Dahllöf, B; Ebefors, K; Kanmert, I; Kerb, S; Lanne, B; Lindahl, C; Miliotis, T; Nyström, AC; Oakes, N; Paulsons, I; von Bahr, H | 1 |
| Favreau, CM; Gutschi, LM; Malcolm, JC; Ooi, TC | 1 |
| Balasubramani, M; Capps, N; Milles, J; Ramachandran, S; Shetty, C | 1 |
| Buse, JB; Deeg, MA; Goldberg, RB; Jacober, SJ; Kendall, DM; Khan, MA; Perez, AT; Tan, MH; Zagar, AJ | 1 |
| Erdmann, E; Hoppe, UC; Michels, G; Rottlaender, D | 1 |
| Eckert, S; Erdmann, E; Forst, T; Lundershausen, R; Scherbaum, WA; Schnell, O; Schumm-Draeger, PM; Standl, E; Tschöpe, D; Walter, H; Weber, M | 1 |
5 review(s) available for rosiglitazone and Dyslipidemia
| Article | Year |
|---|---|
Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors.
Topics: Adipose Tissue; Apolipoproteins; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?
Topics: Biomarkers; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypoglycemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Pioglitazone; Rosiglitazone; Thiazolidinediones; Triglycerides | 2008 |
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Exercise; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Liver Diseases; Metabolic Syndrome; Metformin; Obesity; Oxidative Stress; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss | 2009 |
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hypoglycemic Agents; Oxazoles; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome | 2012 |
[Therapy with glitazones--a risk for cardiovascular disease?].
Topics: Cardiovascular Diseases; Cholesterol, LDL; Contraindications; Diabetes Mellitus, Type 2; Dyslipidemias; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
7 trial(s) available for rosiglitazone and Dyslipidemia
| Article | Year |
|---|---|
Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia.
Topics: Animals; Cholesterol; Dogs; Double-Blind Method; Dyslipidemias; Female; HEK293 Cells; Humans; Hypolipidemic Agents; Indoles; Isoxazoles; Macaca fascicularis; Male; Mice; Mice, Knockout; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Structure-Activity Relationship; Triglycerides | 2015 |
No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.
Topics: Aged; Animals; Aorta; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pioglitazone; Rabbits; Rosiglitazone; Thiazolidinediones; Vasodilation | 2014 |
Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects.
Topics: Adult; Aged; Blood Glucose; Caloric Restriction; Cardiovascular Diseases; Cholesterol; Dyslipidemias; Fatty Acids, Nonesterified; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lipoproteins; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones; Triglycerides | 2008 |
The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Lipid Metabolism; Middle Aged; PPAR alpha; PPAR gamma; Prospective Studies; Rosiglitazone; Thiazolidinediones; Triglycerides; Uric Acid | 2006 |
Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.
Topics: Adolescent; Adult; Aged; Apolipoproteins; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lipid Metabolism; Lipids; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Triglycerides | 2006 |
Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia.
Topics: Adiponectin; Aged; Blood Glucose; Body Mass Index; Cohort Studies; Cytokines; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glyburide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Inflammation; Ligands; Lipids; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Fatty Acids, Nonesterified; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipoproteins; Lipoproteins, HDL; Lipoproteins, VLDL; Pioglitazone; Prospective Studies; Rosiglitazone; Thiazolidinediones | 2007 |
26 other study(ies) available for rosiglitazone and Dyslipidemia
| Article | Year |
|---|---|
Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.
Topics: Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Drug Design; Dyslipidemias; Female; Humans; Hypoglycemic Agents; Male; Mice; Phenyl Ethers; Phenylpropionates; PPAR alpha; PPAR delta; PPAR gamma; Radioligand Assay; Stereoisomerism; Transcriptional Activation; Weight Gain | 2006 |
Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.
Topics: Administration, Oral; Animals; Azetidines; Biological Availability; Copper; Crystallography, X-Ray; Cytochrome P-450 Enzyme Inhibitors; Diabetes Mellitus, Experimental; Dyslipidemias; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Glucose; Mice; Mice, Mutant Strains; Molecular Structure; PPAR alpha; PPAR gamma; Protein Conformation; Stereoisomerism; Structure-Activity Relationship; Triglycerides | 2008 |
Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
Topics: Animals; Chemistry, Pharmaceutical; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Drug Design; Dyslipidemias; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Thiophenes | 2009 |
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
Topics: Animals; Blood Glucose; Butyric Acid; Cell Line; Cholesterol; Cricetinae; Diabetes Mellitus, Type 2; Dogs; Drug Discovery; Dyslipidemias; Female; Humans; Indoles; Male; Mice; PPAR gamma; Rats; Structure-Activity Relationship | 2009 |
Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Design; Dyslipidemias; Glycogen Phosphorylase; Hypoglycemic Agents; Mice; Mice, Inbred Strains; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Quinolines | 2010 |
Thiazolidin-4-one and thiazinan-4-one derivatives analogous to rosiglitazone as potential antihyperglycemic and antidyslipidemic agents.
Topics: 3T3-L1 Cells; Animals; Blood Glucose; Cell Differentiation; Cell Line; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Glucose; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Models, Chemical; Molecular Structure; Muscle, Skeletal; Rosiglitazone; Structure-Activity Relationship; Thiazines; Thiazolidinediones; Thiazolidines; Triglycerides | 2013 |
Momordica charantia ameliorates insulin resistance and dyslipidemia with altered hepatic glucose production and fatty acid synthesis and AMPK phosphorylation in high-fat-fed mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; AMP-Activated Protein Kinases; Animals; Blood Glucose; Diet, High-Fat; Dyslipidemias; Fatty Acid Synthases; Fatty Acids; Fruit; Glucose; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Momordica charantia; Phosphoenolpyruvate Carboxykinase (ATP); Phosphorylation; Plant Extracts; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Triglycerides | 2014 |
CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo.
Topics: 3T3-L1 Cells; Adipose Tissue, White; Aminopyridines; Animals; Anti-Inflammatory Agents; Cell Differentiation; Cell Polarity; Diet, High-Fat; Drug Evaluation, Preclinical; Dyslipidemias; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Macrophages; Male; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcriptional Activation | 2014 |
Synergistic effects of atorvastatin and rosiglitazone on endothelium protection in rats with dyslipidemia.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cytoprotection; Drug Evaluation, Preclinical; Drug Synergism; Dyslipidemias; Endothelium, Vascular; Heptanoic Acids; Male; Myocardium; Oxidative Stress; Pyrroles; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2014 |
Modulation of diabetes and dyslipidemia in diabetic insulin-resistant rats by mangiferin: role of adiponectin and TNF-α.
Topics: Adiponectin; Animals; Diabetes Mellitus, Experimental; Dyslipidemias; Hypoglycemic Agents; Insulin Resistance; Male; Rats; Rosiglitazone; Streptozocin; Thiazolidinediones; Tumor Necrosis Factor-alpha; Xanthones | 2014 |
Padina arborescens Ameliorates Hyperglycemia and Dyslipidemia in C57BL/KsJ-db/db Mice, a Model of Type 2 Diabetes Mellitus.
Topics: Adiponectin; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Disease Models, Animal; Dyslipidemias; Fasting; Glucose Tolerance Test; Glycated Hemoglobin; Glycogen; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Mice; Mice, Inbred C57BL; Phaeophyceae; Rosiglitazone; Thiazolidinediones | 2015 |
Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.
Topics: Aged; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Dyslipidemias; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; United States | 2008 |
Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Animals; Atherosclerosis; Blood Glucose; Body Composition; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Dyslipidemias; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Mice; Mice, Knockout; Rosiglitazone; Simvastatin; Thiazolidinediones; Triglycerides | 2009 |
Effect of ABCA1 variant on atherogenic dyslipidaemia in patients with Type 2 diabetes treated with rosiglitazone.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; PPAR gamma; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Triglycerides; Young Adult | 2009 |
[HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
Topics: Apolipoprotein A-I; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2010 |
Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment.
Topics: Adiponectin; Adipose Tissue; Antiretroviral Therapy, Highly Active; Dyslipidemias; Fatty Acids, Nonesterified; Glycerol; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Lipolysis; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2011 |
AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.
Topics: Animals; Benzoates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Glucose; Humans; Hypoglycemic Agents; Lipid Metabolism; Lipids; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Oxazoles; PPAR alpha; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2012 |
Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice.
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dietary Supplements; Dyslipidemias; Glucose Transporter Type 4; Glycated Hemoglobin; Glycogen; Insulin; Insulin Secretion; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Muscle, Skeletal; Resveratrol; Rosiglitazone; Stilbenes; Thiazolidinediones; Triglycerides | 2012 |
Upregulation of hepatic LRP1 by rosiglitazone: a possible novel mechanism of the beneficial effect of thiazolidinediones on atherogenic dyslipidemia.
Topics: Animals; Dyslipidemias; Hep G2 Cells; Humans; Liver; Low Density Lipoprotein Receptor-Related Protein-1; Rats; Rosiglitazone; Thiazolidinediones | 2012 |
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Topics: Animals; Apolipoprotein E2; Apolipoproteins E; Atherosclerosis; Blood Glucose; Disease Models, Animal; Dyslipidemias; Female; Fenofibrate; Foam Cells; Homeostasis; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Macrophages; Mice; Mice, Mutant Strains; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2005 |
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: response to Goldberg et al.
Topics: Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypoglycemic Agents; Lipids; Rosiglitazone; Thiazolidinediones | 2005 |
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Carbazoles; Disease Models, Animal; Dyslipidemias; Gene Expression; Gluconeogenesis; Hypoglycemic Agents; Insulin Resistance; Lipids; Liver; Liver Glycogen; Muscles; Obesity; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Propionates; Pyrimidines; Rats; Rats, Wistar; Rosiglitazone; Sodium Glutamate; Thiazolidinediones | 2006 |
PPARalpha and PPARgamma regulation of liver and adipose proteins in obese and dyslipidemic rodents.
Topics: Adipose Tissue; Animals; Dyslipidemias; Hypoglycemic Agents; Liver; Male; Mice; Mice, Obese; Peroxisome Proliferators; PPAR alpha; PPAR gamma; Proteome; Pyrimidines; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2006 |
Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy.
Topics: Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2006 |
Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; England; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
[Determining the current position regarding the value of pioglitazone for the therapy of diabetes].
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fractures, Bone; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Osteoporosis, Postmenopausal; Pioglitazone; PPAR gamma; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |